Περιγραφή
Drug and Therapy Development for Triple Negative Breast Cancer
The first comprehensive and up-to-date compilation of modern diagnostic and treatment methods for triple negative breast cancer
In Drug and Therapy Development for Triple Negative Breast Cancer, a team of distinguished practitioners delivers an in-depth and authoritative discussion of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies—including nanotherapeutics and photothermal therapies.
As the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. Readers will also find:
A thorough introduction to HER receptors in breast cancers
Comprehensive explorations of the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer
Application of artificial intelligence to breast cancer diagnosis
New insights on the role of DNA replication stress and genome instability in breast cancer
Perfect for medicinal and pharmaceutical chemists, Drug and Therapy Development for Triple Negative Breast Cancer will also benefit oncologists and professionals working in the pharmaceutical industry or in hospital settings.
About the Author
Pravin Kendrekar works as a Scientist Advisor for White Collar Food & Beverages, Pune, India and T&T Pharmaceuticals, Mumbai, India.
Vinayak Adimule works at the Angadi Institute of Technology and Management in Belagavi, India.
Tara Hurst works in the School of Health Sciences at Birmingham City University in Edgbaston, UK.
